Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.
How this was made
The 30-second read
Why it matters
The cleared studies remove the primary technical barriers identified in the FDA's CRL, positioning the company for a potential expedited review, but approval remains uncertain.
Market read
The news provides fresh regulatory‑risk information for a biotech with high short interest, influencing short‑term price dynamics.
What to watch
The company's manufacturing contracts (e.g., Suboxone film) provide cash flow that could sustain operations even if Anaphylm is delayed.
Background
Aquestive Therapeutics is a micro‑cap biotech focused on an epinephrine film product (Anaphylm) and a broader prodrug platform.
Ticker impact
Q2 2026 results disclosed a cleared study package and a planned FDA resubmission for the Anaphylm epinephrine film in Q3 2026.
Potential modest upside if FDA accepts the resubmission; downside risk if further delays or rejections occur.
The cleared studies address the FDA's prior CRL concerns, but approval is not guaranteed and cash burn remains significant.
Market effects
Improves outlook for niche epinephrine delivery platforms and may lift peers in the injectable drug delivery space.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond specialty pharma investors.
Counterpoint
Short sellers may argue that repeated FDA setbacks and widening losses outweigh the study clearance, keeping the stock under pressure.
Key entities
- CompanyAquestive Therapeutics
Developer of the Anaphylm epinephrine film and other prodrug products.
- RegulatorFDA
U.S. agency that issued the prior Complete Response Letter and will review the resubmission.
